Iron therapy in heart failure patient
Reading File
Finding Sources
Searching PubMed
"iron deficiency" AND "heart failure" AND "intravenous iron"
Finding Sources
Reading Article
Reading Article
Reading File
Reading File
Finding Sources
Reading Article
Reading File
Reading File
I now have comprehensive data from textbooks and the latest trials. Let me compile the full answer.
Iron Therapy in Heart Failure
Prevalence and Pathophysiology
Iron deficiency (ID) is one of the most common comorbidities in heart failure, affecting approximately 30-50% of patients - and it can occur with or without anemia. Contributing mechanisms include:
- Reduced gastrointestinal iron absorption (gut wall edema, congestion)
- Increased gastrointestinal losses (microhemorrhage from NSAIDs, anticoagulation)
- Reduced utilizable iron from the reticuloendothelial system (functional ID)
- Chronic inflammation driving hepcidin upregulation - trapping iron in stores
- Neurohumoral activation affecting iron metabolism
Even without anemia, iron deficiency substantially impairs mitochondrial function in cardiac and skeletal muscle, reducing functional capacity, quality of life, and survival. - Fuster and Hurst's The Heart, 15th Ed.
Definition of Iron Deficiency in Heart Failure
The standard criteria used in trials and endorsed by ESC guidelines:
| Criterion | Value |
|---|---|
| Serum ferritin | < 100 ng/mL (absolute ID) |
| OR ferritin | 100-299 ng/mL + TSAT < 20% (functional ID) |
Hemoglobin level is not required - ID can exist without anemia.
Why NOT Oral Iron?
Oral iron supplementation provides limited benefit in heart failure patients because:
- Poor gastrointestinal absorption (compounded by bowel edema)
- Poor tolerability due to GI side effects (nausea, constipation)
- Chronic inflammation and elevated hepcidin block iron utilization even when absorbed
The IRONOUT-HF trial showed oral iron did not improve peak VO2 or 6-minute walk distance vs. placebo in HFrEF with ID. IV iron is the preferred route.
Intravenous Iron - Available Agents
| Agent | Formulation | Notes |
|---|---|---|
| Ferric carboxymaltose (FCM) | Up to 1000-2000 mg per infusion | Most studied; FAIR-HF, CONFIRM-HF, AFFIRM-AHF, HEART-FID, FAIR-HF2 |
| Ferric derisomaltose (FDI) (iron isomaltoside) | Up to 20 mg/kg single dose | IRONMAN trial; single high-dose administration possible |
| Iron sucrose | 200 mg per infusion (multiple sessions) | Older agent, less convenient |
Key Clinical Trials
Chronic HF Trials
| Trial | N | Agent | Primary Finding |
|---|---|---|---|
| FAIR-HF | 459 | FCM | Improved 6MWT, patient global assessment, NYHA class |
| CONFIRM-HF | 304 | FCM | Improved 6MWT, symptoms, QoL; reduced HF hospitalizations |
| EFFECT-HF | 172 | FCM | Improved peak VO2 vs oral iron |
| HEART-FID | 3065 | FCM | No significant difference in primary composite endpoint (hierarchical: death, HF hosp, 6MWT) |
Acute/Post-Discharge HF Trials
| Trial | N | Agent | Primary Finding |
|---|---|---|---|
| AFFIRM-AHF | 1108 | FCM | Lower total HF hospitalizations + CV death (p=0.059); HF hosp reduced significantly |
| IRONMAN | 1137 | FDI | Trend to reduced HF hosp + CV death; confounded by COVID-19 |
FAIR-HF2 (2025, JAMA)
The latest large RCT (n=1105, HF with LVEF ≤45%) randomized to FCM vs. placebo with a median follow-up of 16.6 months. FCM reduced cardiovascular death or first HF hospitalization (HR 0.79, 95% CI 0.63-0.99; p=0.04), but total HF hospitalizations and the TSAT<20% subgroup endpoints did not reach significance. Safety was similar between groups. - FAIR-HF2 (JAMA, 2025)
2025 Meta-Analysis (Nature Medicine) - Landmark Synthesis
A 2025 Bayesian meta-analysis (Anker et al., Nature Medicine) pooled individual participant data from 6 trials (FAIR-HF, CONFIRM-HF, AFFIRM-AHF, IRONMAN, HEART-FID, FAIR-HF2; n=7,175) and found:
- Composite of recurrent HF hospitalizations + CV mortality at 12 months: RR 0.72 (95% CI 0.55-0.89) - significantly reduced
- Full follow-up: RR 0.81 (95% CI 0.63-0.97)
- Recurrent HF hospitalizations (12 months): RR 0.69 (95% CI 0.48-0.88)
- CV mortality (12 months): HR 0.80 (95% CI 0.61-1.03) - trend, not significant
- All-cause mortality: HR 0.82 (95% CI 0.65-1.03) - no increase in harm
Key insight: Treatment effects were greatest in the first year when doses of IV iron are highest. This suggests dose and timing optimization is key.
Current Guidelines
ESC Heart Failure Guidelines:
- Class I: Screen for iron deficiency in all HF patients
- Class IIa: IV iron (FCM or FDI) in symptomatic HFrEF (LVEF <45%) with iron deficiency (ferritin <100, or ferritin 100-299 with TSAT <20%) to reduce HF hospitalizations and improve symptoms/QoL
- IV iron is recommended regardless of anemia status
Practical Protocol (from major trials):
- Screening: Check serum ferritin + TSAT in all HF patients
- Initial dosing: Calculate iron deficit using Ganzoni formula (or weight/Hb-based table)
- Maintenance: Re-check iron status at 3-4 months; repeat dosing if criteria met
- Monitoring: Ferritin, TSAT, CBC, BP during/after infusion
Who Benefits Most?
Based on IRONMAN and pooled trial data:
- Patients with TSAT < 20% and ferritin > 100 ng/mL (functional ID with high stores) may see greater absolute event reduction
- More anemic patients had greater hemoglobin rise and possibly more symptomatic benefit
- HFrEF (LVEF <45%) is the primary studied population; data in HFpEF is more limited
Practical Considerations
- No oral iron: Not effective in heart failure - reserve for IDA in non-HF context
- Timing: Most benefit when doses are highest (first 12 months post-initiation or post-discharge)
- Post-discharge opportunity: AFFIRM-AHF showed IV iron at discharge after acute HF hospitalization reduces readmissions - a key intervention point
- Safety: Well-tolerated; serious adverse event rates similar to placebo across trials
- Monitoring: Rare hypophosphatemia with FCM (more common than FDI); check phosphate if repeated dosing
- SGLT2 inhibitors also increase hemoglobin/hematocrit and may partially address anemia in HF - consider combination
Summary Table
| Aspect | Key Points |
|---|---|
| Prevalence | 30-50% of HF patients |
| Diagnosis | Ferritin <100, OR ferritin 100-299 + TSAT <20% |
| Preferred route | IV (not oral) |
| Agents | Ferric carboxymaltose, ferric derisomaltose |
| Benefits | Improved symptoms, QoL, 6MWT; reduced HF hospitalizations |
| Mortality benefit | Trend but not definitively proven; meta-analysis favors treatment |
| ESC class | IIa (symptomatic HFrEF + ID) |
| Screen | Class I in all HF |
Recent Evidence Note: The 2025 FAIR-HF2 trial (PMID: 40159390) showed mixed primary endpoints (one significant, two not), and the 2025 Nature Medicine meta-analysis (PMID: 40159279) provides the strongest pooled evidence to date suggesting a real reduction in HF hospitalizations + CV events with IV iron. The mortality benefit remains uncertain and requires further study, particularly on optimal dosing schedules.
Sources: Fuster and Hurst's The Heart, 15th Ed. | Harrison's Principles of Internal Medicine, 22nd Ed. (2025) | Goldman-Cecil Medicine | Anker et al., Nature Medicine 2025 | Anker et al., JAMA 2025 | Cleland et al., Eur Heart J 2024
This is a shared conversation. Sign in to Orris to start your own chat.